Can NAD+ enter cells?

Not passively. Two negative phosphate charges and 663 Da prevent it crossing a lipid bilayer.

An ectoenzyme that cleaves NAD+ outside the cell. Covarrubias 2020 reported senescent cells drive tissue NAD+ decline by increasing its activity.

So how could administered NAD+ have any effect?

Most plausibly by being degraded to smaller precursors that cells can take up and rebuild NAD+ from internally.

NAD+

The Membrane Problem: Why NAD+ Doesn't Get In

JMWritten & reviewed by Jack Muncaster · Founder, UK PeptidesLast reviewed 2026-08-233 cited sources

NAD+ carries two negatively charged phosphates and does not cross plasma membranes. Extracellular NAD+ is also degraded by ectoenzymes including CD38. This is why the research field administers smaller precursors, and why effects following NAD+ administration most plausibly run through its breakdown products.

Key facts

Barrier: Two negative phosphate charges
Membrane crossing: Does not occur passively
Extracellular degradation: CD38 and other ectoenzymes
Likely fate: Cleaved to smaller precursors
Field's approach: Administer NR or NMN instead
NR size: 255.25 Da, far smaller

The physical problem

A lipid bilayer is a hydrophobic barrier, and charged molecules do not cross it without a transporter. NAD+ carries two negative charges on its pyrophosphate bridge at physiological pH and is 663 Da besides. Both properties point the same way: it stays outside unless something actively carries it in.

What happens to it outside

CD38 is an ectoenzyme — an enzyme with its active site facing the outside of the cell — and it cleaves NAD+ as a substrate. So extracellular NAD+ is not simply sitting inert waiting to be taken up; it is being consumed. Covarrubias and colleagues reported in Nature Metabolism in 2020 that senescent cells drive tissue NAD+ decline specifically by increasing CD38 activity, which places this enzyme at the centre of the ageing story.

Research material referenced

NAD+ 500mg — third-party HPLC tested

View — £49.99

Where the breakdown products go

Cleaving NAD+ yields smaller fragments including nicotinamide-containing species, and those are precisely the molecules cells can take up and rebuild NAD+ from. This is the important inference: whatever effect follows administering NAD+ most plausibly proceeds through degradation to precursors, then uptake, then internal resynthesis — not through NAD+ arriving intact.

Which is why the trials use precursors

Nicotinamide riboside at 255.25 Da and nicotinamide mononucleotide at 334.22 Da are both far smaller and both have cellular uptake routes. Every substantial randomised human trial in this field — NADPARK, Orr's 2024 study, Yoshino's 2021 Science paper — used a precursor. That is not because NAD+ was unavailable to those researchers.

What follows practically

Administering NAD+ directly is a less direct route to raising cellular NAD+ than administering a precursor, not a more direct one, because the intact molecule cannot make the final step. It is a genuine pharmacological point and it is almost never made in commercial material about this compound.

Extended research context

The NAD+ deep dive

Deep dive: the compound in this catalogue that is not a peptide

NAD+ contains no amino acids and no peptide bonds. It is a dinucleotide - a nicotinamide nucleotide and an adenine nucleotide joined through a pyrophosphate bridge - which is the structural grammar of ATP and of RNA, not of a protein. It sits in a peptide catalogue because it reaches the same buyers, not because it belongs there. Saying so matters practically rather than pedantically: essentially all of the general handling guidance on this site is written for peptides and is the wrong guidance here. There is no sequence to verify, so purity by amino acid analysis is meaningless. There are no deletion sequences, because there is no stepwise coupling to produce them. Net peptide content, the figure that decides how much material a lyophilised peptide vial actually contains, has no analogue at all. Even the instruction that does carry over - dry, cold, dark - protects different chemistry, guarding glycosidic and pyrophosphate bonds rather than peptide bonds and methionine residues.

Deep dive: why the finished molecule is the least deliverable of the three

NAD+ carries two negatively charged phosphates and weighs 663.4 Da, and neither property is compatible with crossing a lipid bilayer. Extracellular NAD+ is also actively consumed: CD38 is an ectoenzyme with its active site facing outward, and Covarrubias and colleagues reported in Nature Metabolism in 2020 that senescent cells drive tissue NAD+ decline specifically by raising CD38 activity. Put those together and administered NAD+ is a molecule that cannot get in and is being degraded while it waits. Whatever follows most plausibly runs through its breakdown to smaller nicotinamide-containing species, which cells then take up and rebuild NAD+ from internally - which is to say, through exactly the precursors people otherwise take directly. This is why every substantial randomised trial in the field used nicotinamide riboside at 255.25 Da or nicotinamide mononucleotide at 334.22 Da rather than the coenzyme itself. The naming inverts the pharmacology: the finished molecule sounds like the most direct option and is the least.

Deep dive: good early evidence, and the gap that keeps getting closed rhetorically

The randomised human literature here is better than for most of this catalogue. NADPARK was a randomised phase I trial of nicotinamide riboside in Parkinson disease in Cell Metabolism. Orr and colleagues ran a randomised placebo-controlled study in older adults in GeroScience. Yoshino and colleagues published NMN and muscle insulin sensitivity in Science. These are real trials in real journals. What they measured, largely, is whether the intervention does what it is supposed to biologically - and raising a biomarker is not the same as changing an outcome. The step that gets taken rhetorically is from a decline that is real, through a mechanism that is identified, to a benefit that has not been demonstrated. Each link looks small; the chain is not. Nothing in this field approaches the scale of what settled the incretin questions, where TRIUMPH alone enrolled more than 5,800 participants with hard clinical endpoints.

Research applications

▸Cellular NAD+ metabolism and salvage pathway research
▸Sirtuin, PARP and CD38 enzyme activity studies
▸Redox biochemistry and NAD+/NADH ratio measurement
▸Cellular senescence and ageing biology research
▸Mitochondrial function and metabolic assay work
▸Comparative precursor uptake and conversion studies

Handling checklist

✓Verify against CID 5892, 663.4 Da, C21H27N7O14P2 - not by sequence
✓Do not apply peptide purity or net peptide content logic - neither exists here
✓Store lyophilised, cold, dry and protected from light
✓Prepare solutions fresh; nucleotide bonds hydrolyse readily in water
✓Be aware NAD+ and NADH are separately quantifiable oxidation states
✓Identity is confirmed by mass and chromatography against a reference standard

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Applying peptide handling and purity guidance to NAD+

Fix: It is a dinucleotide with no peptide bonds. Sequence verification, protease concerns, disulfide chemistry and net peptide content are all inapplicable.

✗ Assuming administered NAD+ enters cells intact

Fix: Two negative phosphate charges and 663 Da prevent membrane crossing, and CD38 degrades it extracellularly. Effects most plausibly run through breakdown products.

✗ Reading precursor trial results as evidence for NAD+ itself

Fix: Every substantial randomised trial used NR or NMN. NAD+ has essentially no comparable human literature.

✗ Treating a biomarker increase as a demonstrated benefit

Fix: Raising NAD+-related markers is reasonably supported. Durable clinical outcome data does not exist.

✗ Taking a precursor's food supplement status as evidence of efficacy

Fix: Supplement frameworks assess safety for consumption, not efficacy, and permit no therapeutic claims.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Frequently asked questions

Can NAD+ enter cells?: Not passively. Two negative phosphate charges and 663 Da prevent it crossing a lipid bilayer.
What is CD38?: An ectoenzyme that cleaves NAD+ outside the cell. Covarrubias 2020 reported senescent cells drive tissue NAD+ decline by increasing its activity.
So how could administered NAD+ have any effect?: Most plausibly by being degraded to smaller precursors that cells can take up and rebuild NAD+ from internally.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

Written and reviewed by

Jack Muncaster · Founder, UK Peptides

Jack founded UK Peptides in Manchester after repeatedly receiving research compounds with missing or recycled paperwork. He is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate.

How we write and check this content Report a factual error in this article

More NAD+ articles

Popular across the research hub

One flagship guide from every other research category — keep exploring.

← Back to Forum